Experimental ischaemic stroke induces transient cardiac atrophy and dysfunction.
Atrophy
Cardiac dysfunction
Cardiomyocytes
Ischaemic stroke
Left ventricular contractility
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
26
09
2017
revised:
12
03
2018
accepted:
28
06
2018
pubmed:
1
11
2018
medline:
9
4
2020
entrez:
1
11
2018
Statut:
ppublish
Résumé
Stroke can lead to cardiac dysfunction in patients, but the mechanisms underlying the interaction between the injured brain and the heart are poorly understood. The objective of the study is to investigate the effects of experimental murine stroke on cardiac function and molecular signalling in the heart. Mice were subjected to filament-induced left middle cerebral artery occlusion for 30 or 60 min or sham surgery and underwent repetitive micro-echocardiography. Left ventricular contractility was reduced early (24-72 h) but not late (2 months) after brain ischaemia. Cardiac dysfunction was accompanied by a release of high-sensitive cardiac troponin (hsTNT (ng/ml): d1: 7.0 ± 1.0 vs. 25.0 ± 3.2*; d3: 7.3 ± 1.1 vs. 52.2 ± 16.7*; d14: 5.7 ± 0.8 vs. 5.2 ± 0.3; sham vs. 60 min. MCAO; mean ± SEM; *p < 0.05); reduced heart weight (heart weight/tibia length ratio: d1: 6.9 ± 0.2 vs. 6.4 ± 0.1*; d3: 6.7 ± 0.2 vs. 5.8 ± 0.1*; d14: 6.7 ± 0.2 vs. 6.4 ± 03; sham vs. 60 min. MCAO; mean ± SEM; *p < 0.05); resulting from cardiomyocyte atrophy (cardiomyocyte size: d1: 12.8% ± 0.002**; d3: 13.5% ± 0.002**; 14d: 6.3% ± 0.003*; 60 min. MCAO vs. sham; mean ± SEM; **p < 0.01; *p < 0.05), accompanied by increased atrogin-1 and the E3 ubiquitin ligase murf-1. Net norepinephrine but not synthesis was increased, suggesting a reduced norepinephrine release or an increase of norepinephrine re-uptake, resulting in a functional denervation. Transcriptome analysis in cardiac tissue identified the transcription factor peroxisome proliferator-activated receptor gamma as a potential mediator of stroke-induced transcriptional dysregulation involved in cardiac atrophy. Stroke induces a complex molecular response in the heart muscle with immediate but transient cardiac atrophy and dysfunction.
Sections du résumé
BACKGROUND
Stroke can lead to cardiac dysfunction in patients, but the mechanisms underlying the interaction between the injured brain and the heart are poorly understood. The objective of the study is to investigate the effects of experimental murine stroke on cardiac function and molecular signalling in the heart.
METHODS AND RESULTS
Mice were subjected to filament-induced left middle cerebral artery occlusion for 30 or 60 min or sham surgery and underwent repetitive micro-echocardiography. Left ventricular contractility was reduced early (24-72 h) but not late (2 months) after brain ischaemia. Cardiac dysfunction was accompanied by a release of high-sensitive cardiac troponin (hsTNT (ng/ml): d1: 7.0 ± 1.0 vs. 25.0 ± 3.2*; d3: 7.3 ± 1.1 vs. 52.2 ± 16.7*; d14: 5.7 ± 0.8 vs. 5.2 ± 0.3; sham vs. 60 min. MCAO; mean ± SEM; *p < 0.05); reduced heart weight (heart weight/tibia length ratio: d1: 6.9 ± 0.2 vs. 6.4 ± 0.1*; d3: 6.7 ± 0.2 vs. 5.8 ± 0.1*; d14: 6.7 ± 0.2 vs. 6.4 ± 03; sham vs. 60 min. MCAO; mean ± SEM; *p < 0.05); resulting from cardiomyocyte atrophy (cardiomyocyte size: d1: 12.8% ± 0.002**; d3: 13.5% ± 0.002**; 14d: 6.3% ± 0.003*; 60 min. MCAO vs. sham; mean ± SEM; **p < 0.01; *p < 0.05), accompanied by increased atrogin-1 and the E3 ubiquitin ligase murf-1. Net norepinephrine but not synthesis was increased, suggesting a reduced norepinephrine release or an increase of norepinephrine re-uptake, resulting in a functional denervation. Transcriptome analysis in cardiac tissue identified the transcription factor peroxisome proliferator-activated receptor gamma as a potential mediator of stroke-induced transcriptional dysregulation involved in cardiac atrophy.
CONCLUSIONS
Stroke induces a complex molecular response in the heart muscle with immediate but transient cardiac atrophy and dysfunction.
Identifiants
pubmed: 30378296
doi: 10.1002/jcsm.12335
pmc: PMC6438414
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-62Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Cerebrovasc Dis. 2010;30(4):410-7
pubmed: 20720410
Neurology. 2001 Sep 11;57(5):833-8
pubmed: 11552013
Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H997-H1006
pubmed: 19168726
Clin Chem. 2010 Feb;56(2):254-61
pubmed: 19959623
EMBO Mol Med. 2014 Sep 05;6(10):1231-45
pubmed: 25193973
Int J Cardiol. 2014 Sep;176(1):206-10
pubmed: 25049007
Mol Metab. 2015 Nov 26;5(2):67-78
pubmed: 26909315
Cell. 2010 Oct 1;143(1):35-45
pubmed: 20887891
Ann Neurol. 2017 Nov;82(5):729-743
pubmed: 29023958
Genetics. 2003 Oct;165(2):747-57
pubmed: 14573485
Stroke. 2009 Aug;40(8):2849-58
pubmed: 19443795
Int J Cardiol. 2013 Sep 10;167(6):2441-8
pubmed: 23415170
Cerebrovasc Dis. 2014;37(2):147-52
pubmed: 24481543
Circulation. 2014 Oct 7;130(15):1262-73
pubmed: 25124496
BMC Neurol. 2013 Sep 23;13:122
pubmed: 24053888
Circ Res. 2009 Jul 2;105(1):80-8
pubmed: 19498199
Stroke. 2009 Jul;40(7):2560-3
pubmed: 19443809
Trends Cardiovasc Med. 2010 Jan;20(1):12-6
pubmed: 20685572
Brain Behav Immun. 2014 Oct;41:200-9
pubmed: 24886966
Transl Stroke Res. 2017 Aug;8(4):374-385
pubmed: 28101763
Nat Protoc. 2013 Aug;8(8):1551-66
pubmed: 23868073
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083
pubmed: 29098794
Int J Cardiovasc Imaging. 2015 Apr;31(4):669-79
pubmed: 25627778
J Stroke Cerebrovasc Dis. 2015 Oct;24(10):2390-6
pubmed: 26236002
Cardiovasc Res. 2014 Oct 1;104(1):15-23
pubmed: 25082846
N Engl J Med. 2015 Dec 31;373(27):2689-91
pubmed: 26716925
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):54-62
pubmed: 30378296
J Clin Invest. 2013 Mar;123(3):1359-70
pubmed: 23434587
BMC Neurol. 2011 Aug 08;11:98
pubmed: 21824425
Clin Exp Pharmacol Physiol. 2003 Nov;30(11):860-6
pubmed: 14678251
Physiology (Bethesda). 2007 Dec;22:373-9
pubmed: 18073410
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Compr Physiol. 2015 Jul 1;5(3):1241-63
pubmed: 26140717
Cochrane Database Syst Rev. 2015 Oct 29;(10):CD010693
pubmed: 26511368
N Engl J Med. 2016 Apr 7;374(14):1321-31
pubmed: 26886418
Circ Res. 2005 Aug 19;97(4):372-9
pubmed: 16051889
PLoS One. 2017 Mar 10;12(3):e0172070
pubmed: 28282374
PLoS One. 2013;8(3):e59726
pubmed: 23555761
J Clin Invest. 2007 Oct;117(10):2791-801
pubmed: 17823655
Cardiovasc Res. 2013 Feb 1;97(2):240-50
pubmed: 23090606